[{"orgOrder":0,"company":"Alliance Pharmaceutical Company","sponsor":"Valeo Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Tetracaine Hydrochloride","moa":"Sodium channel alpha subunits","graph1":"Neurology","graph2":"Approved","graph3":"Alliance Pharmaceutical Company","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Alliance Pharmaceutical Company \/ Valeo Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Alliance Pharmaceutical Company \/ Valeo Pharma"}]

Find Clinical Drug Pipeline Developments & Deals by Alliance Pharmaceutical Company

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          BioFlorida Conference
                          Not Confirmed
                          BioFlorida Conference
                          Not Confirmed

                          Details : Valeo Pharm has entered into a licensing agreement with Alliance Pharma plc for the exclusive commercialization rights to AmetopTM Gel (Tetracaine hydrochloride gel) in Canada.

                          Brand Name : Ametop

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          April 28, 2020

                          Lead Product(s) : Tetracaine Hydrochloride

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved

                          Sponsor : Valeo Pharma

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank